Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its ...

Bernstein analyst Florent Cespedes maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

European shares were at a record high on Friday, led by technology and healthcare stocks, even as caution prevailed ahead of ...

Jefferies analyst Peter Welford maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance ...

The Bureau of Economic Analysis will release the personal consumption expenditures, or PCE, price index for December on Friday at 8:30 a.m. ET, as part of its personal income and outlays report. Gold ...

Japan is considering offering support for a $44 billion gas pipeline in Alaska as it seeks to court U.S. President Donald ...

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

Coherus BioSciences, Inc.’s CHRS share price has surged by 10.66%, which has investors questioning if this is right time to sell.